Molecular targeting remains to be a promising approach in cancer medicine. Knowledge 43 about molecular properties such as overexpression of G protein-coupled receptors 44 (GPCRs) is thereby offering a powerful tool for tumor-selective imaging and treatment of 45 cancer cells. We utilized chemerin-based peptides for CMKLR1 receptor targeting in a 46 breast cancer xenograft model. By conjugation with radiolabeled chelator 1,4,7,10-47 tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), we obtained a family of highly 48 specific and affine tracers for hybrid in vivo imaging with positron emission tomography 49 (PET)/ magnetic resonance (MR) and concomitant biodistribution studies.
USA) and further homogenized by moving the pestle up and down (approx. 30 times).
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After centrifugation for 30 minutes (4 °C und 40.000 g), the process was repeated, before 220 cell and tissue homogenates were resuspended in 1 mL membrane isolation buffer, 3C, white arrow). The most hydrophobic CG34 tracer, with ADX as a linker, also led to 349 specific tumor uptake ( Figure 3D , white arrow), but also high kidney (yellow arrow) and 350 apparent liver uptake (red arrow). For the tracer 68 Ga-DOTA-AHX-CG36, kidney and liver 351 signals were high but almost no tumor uptake could be detected ( Figure 3E ). Based on 352 these initial in vivo findings, the three most promising tracers 68 Ga-DOTA-AHX-CG34, Figure 4A ). In addition to in vivo imaging, tumor-bearing mice were injected 365 with approximately 10 MBq of radiotracer and sacrificed after one and two hours, to a DU4475 tumor uptake of about 4.5% IA/g and was 2-fold less in the A549 tumor with 369 approx. 2.3% IA/g. Furthermore, higher values were measured for spleen (approx. 4.9%
370
IA/g) and, due to the predominant renal excretion of peptides, for kidneys (approx. 5.8%
371
IA/g). The DU4475 uptake decreased to approx. 2.9% IA/g, whereas the kidney signal 372 increased up to approx. 6.5% IA/g two hours post-injection (lower panel, Figure 4A ). For Figure 4B ). In addition to overall higher values one hour after injection, liver (approx. 378 14.2% IA/g), kidney (10.3% IA/g) and spleen (7.8% IA/g) uptakes were the most profound 379 off-target effects. However, with approx. 6.2% IA/g for CMKLR1-positive DU4475 tumors 380 and approx. 2.7% IA/g for target-negative A549 tumors, PET results and tracer specificity 381 could be confirmed. After two hours, DU4475 uptake declined by 1.5-fold to approx. 4.2%
382
IA/g and a distinct liver uptake (approx. 12.5% IA/g) persisted. Kinetic measurements of 383 tracer concentration in tumors, kidneys and liver demonstrated a delayed kidney peak for 384 68 Ga-DOTA-KCap-CG34, the most hydrophobic molecule, with rapid washout from 385 kidneys for both 68 Ga-DOTA-AHX-CG34 and 68 Ga-DOTA-ADX-CG34 ( Figure S2 ). While 386 the other two tracers showed a small decline in the DU4475 tumor, 68 Ga-DOTA-ADX-
387
CG34 appeared to gain in tumor activity until 90 min p.i. DU4475 tumor uptake (approx. 5.1% IA/g) and the high kidney (approx. 6.5% IA/g) and 404 spleen (approx. 6.3% IA/g) values ( Figure 5C ). CMKLR1 blocking with an excess of CG34 405 led to an overall low tissue and organ radioactivity except for strong kidney uptake (8.6%
406
IA/g) and excretion into the urinary bladder. The tracer uptake within DU4475 tumors could 407 be blocked by a factor of 6.4 to approximately 0.8% IA/g ( Figure 5D ).
409
A summary of all biodistribution data including calculated tissue radioactivity ratios for the 410 three most promising tracers 68 Ga-DOTA-AHX-CG34, 68 Ga-DOTA-KCap-CG34 and 68 Ga-
411
DOTA-ADX-CG34 is presented in Table 1 . Use of these CMKLR1 tracers resulted in 412 distinct target-specific DU4475 tumor uptake with 5.1% IA/g ( 68 Ga-DOTA-AHX-CG34), 413 4.3% IA/g ( 68 Ga-DOTA-KCap-CG34) and 6.2% IA/g ( 68 Ga-DOTA-ADX-CG34). All three 414 of them showed favorable tumor-to-kidneys ratios with 0.9, 0.7 and 0.8. CMKLR1 415 specificity could be proven by 1.8-fold (5.1 vs. 3.0% IA/g), 1.9-fold (4.3 vs. 2.3% IA/g) and 
420
The most stable and durable tumor uptake was achieved by 68 Ga-DOTA-AHX-CG34 with 421 4.9% IA/g (approx. 96% of the 1 h-value) after two hours, whereas uptake of the KCap-422 linked (approx. 67%) and ADX-linked (approx. 68%) tracers declined faster within two 423 hours after injection. The highest overall non-tumor uptake values were seen with 68 Ga-
424
DOTA-ADX-CG34, with considerable liver (14.2% IA/g) and kidney (10.3% IA/g) uptake 425 and hence, the lowest tissue radioactivity ratios for the DU4475 tumor. In the design of our tracers, we followed the hypothesis that tumor uptake and 457 biodistribution may depend on a balance of hydrophobic and hydrophilic properties within 458 the molecule. Therefore, we chose not only to make use of a more hydrophilic and a more 459 hydrophobic CMKLR1 peptide ligand analog, but also to take advantage of different 460 linkers to introduce a varying degree of hydrophobicity into the conjugates. As DOTA with 461 its four carboxylic groups confers rather strong hydrophilic features, we chose to 462 compensate this with mainly hydrophobic linker moieties: 6-aminohexanoic acid (AHX), (Figure 2A) . A set of five resulting DOTA peptide conjugates was tested in vitro prior to 466 the animal study. Of note, all these tracers proved to be of high affinity and functional 467 activity, with IC50 and EC50 values being below 2 nM ( Figure 2D ). Affinity also did not 468 change significantly upon complexation of DOTA with non-radioactive gallium, and if so,
469
IC 50 values even decreased. This was in many ways unexpected as we and others had 470 often experienced an impairment of the binding and activating capacity of ligands upon 471 conjugation with a linker and a reporter such as a chelator or dye molecule [34] [35] [36] [37] .
472
Likewise, the affinity of such a conjugate may be affected by the coordination of a 473 radiometal ion [38] . The structural requirements of chemerin analogs binding to CMKLR1 474 obviously allow for a broad variety of additions to the N-terminus of the nonameric peptide.
475
Even though the two most potent conjugates were the ones with the shortest linkers (AHX 476 and ADX), differences were small and a significant systematic influence of linker 477 hydrophobicity or length on affinity or activity was not observed.
478
The initial PET studies using all five tracers revealed a clear difference regarding tumor 479 uptake and biodistribution: the most hydrophilic conjugate ( 68 Ga-DOTA-TTDS-CG34) and 480 the most hydrophobic conjugate ( 68 Ga-DOTA-AHX-CG36) both showed lower tumor 481 uptake and higher kidney uptake than the three conjugates with balanced hydrophilicity in 482 the molecule (Figure 3 ). This was also confirmed by results from biodistribution 483 experiments: for both tracers, there was no clear difference in uptake between target-484 positive and target-negative tumor ( Figure S1 and Table S1 ). These results may indicate 485 the validity of our hypothesis that sufficient and specific tumor uptake may be achieved 486 best using a conjugate with moderate, balanced hydrophilicity. Both highly hydrophobic 487 and strongly hydrophilic tracers may primarily yield unspecific uptake in kidney and liver.
488
By peptide optimization and conjugation, we were able to obtain a family of five high-489 potency, high-affinity molecular probes for further in vivo application as radioactive 490 tracers. In addition to PET/MRI scans one and two hours post-injection, ex vivo 491 biodistribution studies were performed to assess quantitative values for tissue uptake. 
496
Kidney uptake often limits therapeutic use of tracers. For the three best tracers described 497 in this study, renal uptake was between 5.8 to 10.3% IA/g, resulting in favorable tumor-to-498 kidney ratios of 0.7 to 0.9 at one hour post injection. Further evidence for the specificity of KCap and ADX led to delayed and prolonged kidney uptake, possibly due to plasma 508 protein binding or metabolization in the liver ( Figure S2 ).
509
While a tumor uptake of 4-6% represents a promising targeting result for these first 510 CMKLR1 tracers, several options for an improvement remain. One current limitation, 
